Science
A new chapter in targeting kinase enzymes in cancer
Publication: Nature
Author: Alice T. Shaw
Source published: 29/09/2026, 00:00:00 UTC
Briefing created: 29/09/2026, 10:36:53 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 29/09/2026, 10:35:25 UTC.
Briefings
A new chapter in cancer treatment is emerging as targeted protein degraders are replacing or supplementing tyrosine kinase inhibitors. The article, published in Nature on September 29, 2026, highlights this shift in precision oncology strategies.
Key points
- Targeted protein degraders are being developed as a potential alternative or complementary therapy to tyrosine kinase inhibitors for cancer treatment.
- The article is a preprint available at doi:10.1038/d41586-026-02776-y, published online on September 29, 2026, in Nature.
Context and limitations
The evidence is limited to a single preprint article from Nature. Specific clinical trial data, patient outcomes, or comparative efficacy metrics are not provided in the available source.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 29/09/2026, 10:36:53 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeieimiltltihxunqyk4p6seck2rwrzqya5sokvyxwrtjnvwnfo43na